Activity of apremilast in a patient with severe pemphigus vulgaris: case report Article Swipe
C. Delvaux
,
G. Bohelay
,
Ishaï-Yaacov Sitbon
,
I. Soued
,
M. Alexandre
,
Joël Cucherousset
,
Laurent Gilardin
,
Antoine Diep
,
F. Caux
,
C. Le Roux‐Villet
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2024.1404185
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2024.1404185
Introduction Although the treatment for pemphigus vulgaris (PV) has been revolutionized by the use of rituximab combined with corticosteroids, new effective therapies with a better safety profile are needed. Observation A 67-year-old woman was diagnosed with severe mucosal PV, which was initially misdiagnosed as atypical Behçet’s disease. Following an unsuccessful colchicine treatment, significant improvement was observed upon the introduction of apremilast: reduced pain, fewer lesions, and a stabilized weight. The discontinuation of apremilast led to a rapid relapse. Retrospective analysis through anti-Dsg3 ELISA indicated a gradual decrease in antibody levels during the apremilast treatment. Discussion Apremilast, a phosphodiesterase 4 inhibitor approved for psoriasis and Behçet’s disease’s related oral ulcers treatment, demonstrated its efficacy in this PV case. This is the second case report highlighting the effectiveness of apremilast for PV treatment. Apremilast’s ability to upregulate cyclic adenosine monophosphate (cAMP) levels appears to contribute to the stabilization of keratinocyte adhesion. Conclusion Apremilast may be a promising therapeutic option for the treatment of pemphigus, with an innovative mechanism of action, no induced immunosuppression, and good tolerance. It could be a good alternative to steroids, in the treatment regimen of steroids combined with rituximab.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fimmu.2024.1404185
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdf
- OA Status
- gold
- Cited By
- 8
- References
- 11
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4400014695
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4400014695Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fimmu.2024.1404185Digital Object Identifier
- Title
-
Activity of apremilast in a patient with severe pemphigus vulgaris: case reportWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-06-25Full publication date if available
- Authors
-
C. Delvaux, G. Bohelay, Ishaï-Yaacov Sitbon, I. Soued, M. Alexandre, Joël Cucherousset, Laurent Gilardin, Antoine Diep, F. Caux, C. Le Roux‐VilletList of authors in order
- Landing page
-
https://doi.org/10.3389/fimmu.2024.1404185Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdfDirect OA link when available
- Concepts
-
Apremilast, Medicine, Pemphigus vulgaris, Discontinuation, Rituximab, Thalidomide, Dermatology, Pemphigus, Psoriasis, Immunology, Internal medicine, Antibody, Psoriatic arthritis, Multiple myelomaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
8Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 7, 2024: 1Per-year citation counts (last 5 years)
- References (count)
-
11Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4400014695 |
|---|---|
| doi | https://doi.org/10.3389/fimmu.2024.1404185 |
| ids.doi | https://doi.org/10.3389/fimmu.2024.1404185 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38983857 |
| ids.openalex | https://openalex.org/W4400014695 |
| fwci | 7.32647925 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D010392 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Pemphigus |
| mesh[2].qualifier_ui | Q000175 |
| mesh[2].descriptor_ui | D010392 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | diagnosis |
| mesh[2].descriptor_name | Pemphigus |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D005260 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Female |
| mesh[4].qualifier_ui | Q000031 |
| mesh[4].descriptor_ui | D013792 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | analogs & derivatives |
| mesh[4].descriptor_name | Thalidomide |
| mesh[5].qualifier_ui | Q000627 |
| mesh[5].descriptor_ui | D013792 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | therapeutic use |
| mesh[5].descriptor_name | Thalidomide |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000368 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Aged |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D016896 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Treatment Outcome |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D000894 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[9].qualifier_ui | Q000627 |
| mesh[9].descriptor_ui | D058988 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | therapeutic use |
| mesh[9].descriptor_name | Phosphodiesterase 4 Inhibitors |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | Q000188 |
| mesh[11].descriptor_ui | D010392 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | drug therapy |
| mesh[11].descriptor_name | Pemphigus |
| mesh[12].qualifier_ui | Q000175 |
| mesh[12].descriptor_ui | D010392 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | diagnosis |
| mesh[12].descriptor_name | Pemphigus |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D005260 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Female |
| mesh[14].qualifier_ui | Q000031 |
| mesh[14].descriptor_ui | D013792 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | analogs & derivatives |
| mesh[14].descriptor_name | Thalidomide |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D013792 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Thalidomide |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000368 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Aged |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D016896 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Treatment Outcome |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D000894 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[19].qualifier_ui | Q000627 |
| mesh[19].descriptor_ui | D058988 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | therapeutic use |
| mesh[19].descriptor_name | Phosphodiesterase 4 Inhibitors |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D010392 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Pemphigus |
| mesh[22].qualifier_ui | Q000175 |
| mesh[22].descriptor_ui | D010392 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | diagnosis |
| mesh[22].descriptor_name | Pemphigus |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D005260 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Female |
| mesh[24].qualifier_ui | Q000031 |
| mesh[24].descriptor_ui | D013792 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | analogs & derivatives |
| mesh[24].descriptor_name | Thalidomide |
| mesh[25].qualifier_ui | Q000627 |
| mesh[25].descriptor_ui | D013792 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | therapeutic use |
| mesh[25].descriptor_name | Thalidomide |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000368 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Aged |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D016896 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Treatment Outcome |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D000894 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Anti-Inflammatory Agents, Non-Steroidal |
| mesh[29].qualifier_ui | Q000627 |
| mesh[29].descriptor_ui | D058988 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | therapeutic use |
| mesh[29].descriptor_name | Phosphodiesterase 4 Inhibitors |
| type | article |
| title | Activity of apremilast in a patient with severe pemphigus vulgaris: case report |
| biblio.issue | |
| biblio.volume | 15 |
| biblio.last_page | 1404185 |
| biblio.first_page | 1404185 |
| topics[0].id | https://openalex.org/T11730 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Autoimmune Bullous Skin Diseases |
| topics[1].id | https://openalex.org/T11917 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9951000213623047 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Coagulation, Bradykinin, Polyphosphates, and Angioedema |
| topics[2].id | https://openalex.org/T12438 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9706000089645386 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2745 |
| topics[2].subfield.display_name | Rheumatology |
| topics[2].display_name | Urticaria and Related Conditions |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C2781427535 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9753758907318115 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q2858961 |
| concepts[0].display_name | Apremilast |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8920283317565918 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2781313415 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7190724015235901 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3899001 |
| concepts[2].display_name | Pemphigus vulgaris |
| concepts[3].id | https://openalex.org/C2778715236 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5501070618629456 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[3].display_name | Discontinuation |
| concepts[4].id | https://openalex.org/C2780653079 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5443536639213562 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q412323 |
| concepts[4].display_name | Rituximab |
| concepts[5].id | https://openalex.org/C2779609412 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5336267352104187 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q203174 |
| concepts[5].display_name | Thalidomide |
| concepts[6].id | https://openalex.org/C16005928 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5212829113006592 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[6].display_name | Dermatology |
| concepts[7].id | https://openalex.org/C2781327288 |
| concepts[7].level | 2 |
| concepts[7].score | 0.5043379068374634 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1483214 |
| concepts[7].display_name | Pemphigus |
| concepts[8].id | https://openalex.org/C2780564577 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4774101972579956 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q179945 |
| concepts[8].display_name | Psoriasis |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.30092471837997437 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.29568177461624146 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C159654299 |
| concepts[11].level | 2 |
| concepts[11].score | 0.10925358533859253 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[11].display_name | Antibody |
| concepts[12].id | https://openalex.org/C2776260265 |
| concepts[12].level | 3 |
| concepts[12].score | 0.07558989524841309 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q511097 |
| concepts[12].display_name | Psoriatic arthritis |
| concepts[13].id | https://openalex.org/C2776364478 |
| concepts[13].level | 2 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[13].display_name | Multiple myeloma |
| keywords[0].id | https://openalex.org/keywords/apremilast |
| keywords[0].score | 0.9753758907318115 |
| keywords[0].display_name | Apremilast |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8920283317565918 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/pemphigus-vulgaris |
| keywords[2].score | 0.7190724015235901 |
| keywords[2].display_name | Pemphigus vulgaris |
| keywords[3].id | https://openalex.org/keywords/discontinuation |
| keywords[3].score | 0.5501070618629456 |
| keywords[3].display_name | Discontinuation |
| keywords[4].id | https://openalex.org/keywords/rituximab |
| keywords[4].score | 0.5443536639213562 |
| keywords[4].display_name | Rituximab |
| keywords[5].id | https://openalex.org/keywords/thalidomide |
| keywords[5].score | 0.5336267352104187 |
| keywords[5].display_name | Thalidomide |
| keywords[6].id | https://openalex.org/keywords/dermatology |
| keywords[6].score | 0.5212829113006592 |
| keywords[6].display_name | Dermatology |
| keywords[7].id | https://openalex.org/keywords/pemphigus |
| keywords[7].score | 0.5043379068374634 |
| keywords[7].display_name | Pemphigus |
| keywords[8].id | https://openalex.org/keywords/psoriasis |
| keywords[8].score | 0.4774101972579956 |
| keywords[8].display_name | Psoriasis |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.30092471837997437 |
| keywords[9].display_name | Immunology |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.29568177461624146 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/antibody |
| keywords[11].score | 0.10925358533859253 |
| keywords[11].display_name | Antibody |
| keywords[12].id | https://openalex.org/keywords/psoriatic-arthritis |
| keywords[12].score | 0.07558989524841309 |
| keywords[12].display_name | Psoriatic arthritis |
| language | en |
| locations[0].id | doi:10.3389/fimmu.2024.1404185 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2595292759 |
| locations[0].source.issn | 1664-3224 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1664-3224 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Immunology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Immunology |
| locations[0].landing_page_url | https://doi.org/10.3389/fimmu.2024.1404185 |
| locations[1].id | pmid:38983857 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in immunology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38983857 |
| locations[2].id | pmh:oai:dipot.ulb.ac.be:2013/376779 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401063 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) |
| locations[2].source.host_organization | https://openalex.org/I132053463 |
| locations[2].source.host_organization_name | Université Libre de Bruxelles |
| locations[2].source.host_organization_lineage | https://openalex.org/I132053463 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:ulb-repo/semantics/openurl/article |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in immunology, 15 |
| locations[2].landing_page_url | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/376779 |
| locations[3].id | pmh:oai:doaj.org/article:5c053e59c06a4fd696092c03b37593b9 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Frontiers in Immunology, Vol 15 (2024) |
| locations[3].landing_page_url | https://doaj.org/article/5c053e59c06a4fd696092c03b37593b9 |
| locations[4].id | pmh:oai:pubmedcentral.nih.gov:11231183 |
| locations[4].is_oa | True |
| locations[4].source.id | https://openalex.org/S2764455111 |
| locations[4].source.issn | |
| locations[4].source.type | repository |
| locations[4].source.is_oa | False |
| locations[4].source.issn_l | |
| locations[4].source.is_core | False |
| locations[4].source.is_in_doaj | False |
| locations[4].source.display_name | PubMed Central |
| locations[4].source.host_organization | https://openalex.org/I1299303238 |
| locations[4].source.host_organization_name | National Institutes of Health |
| locations[4].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[4].license | other-oa |
| locations[4].pdf_url | |
| locations[4].version | submittedVersion |
| locations[4].raw_type | Text |
| locations[4].license_id | https://openalex.org/licenses/other-oa |
| locations[4].is_accepted | False |
| locations[4].is_published | False |
| locations[4].raw_source_name | Front Immunol |
| locations[4].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11231183 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5093280756 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | C. Delvaux |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I132053463 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Dermatology, Saint-Pierre and Brugmann University Hospitals, Université Libre de Bruxelles, Brussels, Belgium |
| authorships[0].institutions[0].id | https://openalex.org/I132053463 |
| authorships[0].institutions[0].ror | https://ror.org/01r9htc13 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I132053463 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Université Libre de Bruxelles |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Cheyenne Delvaux |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Dermatology, Saint-Pierre and Brugmann University Hospitals, Université Libre de Bruxelles, Brussels, Belgium |
| authorships[1].author.id | https://openalex.org/A5059142424 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-8792-979X |
| authorships[1].author.display_name | G. Bohelay |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[1].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[1].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[1].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[1].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[1].institutions[1].country_code | FR |
| authorships[1].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Gérôme Bohelay |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[2].author.id | https://openalex.org/A5048491787 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ishaï-Yaacov Sitbon |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[2].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[2].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[2].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[2].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[2].institutions[1].country_code | FR |
| authorships[2].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ishaï-Yaacov Sitbon |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[3].author.id | https://openalex.org/A5070406483 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | I. Soued |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of ENT, Avicenne Hospital AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[3].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[3].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[3].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[3].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[3].institutions[1].country_code | FR |
| authorships[3].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Isaac Soued |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of ENT, Avicenne Hospital AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[4].author.id | https://openalex.org/A5074758121 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-0155-9239 |
| authorships[4].author.display_name | M. Alexandre |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[4].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[4].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[4].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[4].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[4].institutions[1].country_code | FR |
| authorships[4].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Marina Alexandre |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[5].author.id | https://openalex.org/A5108780068 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Joël Cucherousset |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Pathology, Avicenne Hospital AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[5].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[5].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[5].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[5].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[5].institutions[1].country_code | FR |
| authorships[5].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Joël Cucherousset |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Pathology, Avicenne Hospital AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[6].author.id | https://openalex.org/A5052054371 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9212-0859 |
| authorships[6].author.display_name | Laurent Gilardin |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210149664 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Jean-Verdier Hospital, Bondy, France |
| authorships[6].institutions[0].id | https://openalex.org/I4210149664 |
| authorships[6].institutions[0].ror | https://ror.org/04pag4b70 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210149664 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Hôpital Jean-Verdier |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Laurent Gilardin |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Internal Medicine, Jean-Verdier Hospital, Bondy, France |
| authorships[7].author.id | https://openalex.org/A5099477504 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Antoine Diep |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210144610 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Immunology, Saint-Louis Hospital, Paris, France |
| authorships[7].institutions[0].id | https://openalex.org/I4210144610 |
| authorships[7].institutions[0].ror | https://ror.org/049am9t04 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210097159, https://openalex.org/I4210144610 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Hôpital Saint-Louis |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Antoine Diep |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Immunology, Saint-Louis Hospital, Paris, France |
| authorships[8].author.id | https://openalex.org/A5028087983 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-9552-0882 |
| authorships[8].author.display_name | F. Caux |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[8].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[8].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[8].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[8].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[8].institutions[1].country_code | FR |
| authorships[8].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Frédéric Caux |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[9].author.id | https://openalex.org/A5046679600 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | C. Le Roux‐Villet |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| authorships[9].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[9].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[9].institutions[1].id | https://openalex.org/I4210091279 |
| authorships[9].institutions[1].ror | https://ror.org/0199hds37 |
| authorships[9].institutions[1].type | education |
| authorships[9].institutions[1].lineage | https://openalex.org/I4210091279 |
| authorships[9].institutions[1].country_code | FR |
| authorships[9].institutions[1].display_name | Université Sorbonne Paris Nord |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Christelle Le Roux-Villet |
| authorships[9].is_corresponding | True |
| authorships[9].raw_affiliation_strings | Department of Dermatology and Referral Center for Autoimmune Bullous Diseases MALIBUL, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Activity of apremilast in a patient with severe pemphigus vulgaris: case report |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T11730 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Autoimmune Bullous Skin Diseases |
| related_works | https://openalex.org/W2076071554, https://openalex.org/W3089286105, https://openalex.org/W4287009336, https://openalex.org/W2091245624, https://openalex.org/W3028640111, https://openalex.org/W3167916903, https://openalex.org/W2058712729, https://openalex.org/W1862250341, https://openalex.org/W2016457205, https://openalex.org/W2902511548 |
| cited_by_count | 8 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 7 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 5 |
| best_oa_location.id | doi:10.3389/fimmu.2024.1404185 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2595292759 |
| best_oa_location.source.issn | 1664-3224 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1664-3224 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Immunology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Immunology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fimmu.2024.1404185 |
| primary_location.id | doi:10.3389/fimmu.2024.1404185 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2595292759 |
| primary_location.source.issn | 1664-3224 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1664-3224 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Immunology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1404185/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Immunology |
| primary_location.landing_page_url | https://doi.org/10.3389/fimmu.2024.1404185 |
| publication_date | 2024-06-25 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W1907326545, https://openalex.org/W2135985608, https://openalex.org/W2602517913, https://openalex.org/W3080818382, https://openalex.org/W4226396914, https://openalex.org/W1919283206, https://openalex.org/W2984666751, https://openalex.org/W3096062257, https://openalex.org/W4313814633, https://openalex.org/W2900290555, https://openalex.org/W4310706742 |
| referenced_works_count | 11 |
| abstract_inverted_index.4 | 98 |
| abstract_inverted_index.A | 30 |
| abstract_inverted_index.a | 23, 66, 75, 84, 96, 153, 177 |
| abstract_inverted_index.It | 174 |
| abstract_inverted_index.PV | 115, 129 |
| abstract_inverted_index.an | 48, 163 |
| abstract_inverted_index.as | 43 |
| abstract_inverted_index.be | 152, 176 |
| abstract_inverted_index.by | 11 |
| abstract_inverted_index.in | 87, 113, 182 |
| abstract_inverted_index.is | 118 |
| abstract_inverted_index.no | 168 |
| abstract_inverted_index.of | 14, 59, 71, 126, 146, 160, 166, 186 |
| abstract_inverted_index.to | 74, 133, 141, 143, 180 |
| abstract_inverted_index.PV, | 38 |
| abstract_inverted_index.The | 69 |
| abstract_inverted_index.and | 65, 103, 171 |
| abstract_inverted_index.are | 27 |
| abstract_inverted_index.for | 4, 101, 128, 157 |
| abstract_inverted_index.has | 8 |
| abstract_inverted_index.its | 111 |
| abstract_inverted_index.led | 73 |
| abstract_inverted_index.may | 151 |
| abstract_inverted_index.new | 19 |
| abstract_inverted_index.the | 2, 12, 57, 91, 119, 124, 144, 158, 183 |
| abstract_inverted_index.use | 13 |
| abstract_inverted_index.was | 33, 40, 54 |
| abstract_inverted_index.(PV) | 7 |
| abstract_inverted_index.This | 117 |
| abstract_inverted_index.been | 9 |
| abstract_inverted_index.case | 121 |
| abstract_inverted_index.good | 172, 178 |
| abstract_inverted_index.oral | 107 |
| abstract_inverted_index.this | 114 |
| abstract_inverted_index.upon | 56 |
| abstract_inverted_index.with | 17, 22, 35, 162, 189 |
| abstract_inverted_index.ELISA | 82 |
| abstract_inverted_index.case. | 116 |
| abstract_inverted_index.could | 175 |
| abstract_inverted_index.fewer | 63 |
| abstract_inverted_index.pain, | 62 |
| abstract_inverted_index.rapid | 76 |
| abstract_inverted_index.which | 39 |
| abstract_inverted_index.woman | 32 |
| abstract_inverted_index.(cAMP) | 138 |
| abstract_inverted_index.better | 24 |
| abstract_inverted_index.cyclic | 135 |
| abstract_inverted_index.during | 90 |
| abstract_inverted_index.levels | 89, 139 |
| abstract_inverted_index.option | 156 |
| abstract_inverted_index.report | 122 |
| abstract_inverted_index.safety | 25 |
| abstract_inverted_index.second | 120 |
| abstract_inverted_index.severe | 36 |
| abstract_inverted_index.ulcers | 108 |
| abstract_inverted_index.ability | 132 |
| abstract_inverted_index.action, | 167 |
| abstract_inverted_index.appears | 140 |
| abstract_inverted_index.gradual | 85 |
| abstract_inverted_index.induced | 169 |
| abstract_inverted_index.mucosal | 37 |
| abstract_inverted_index.needed. | 28 |
| abstract_inverted_index.profile | 26 |
| abstract_inverted_index.reduced | 61 |
| abstract_inverted_index.regimen | 185 |
| abstract_inverted_index.related | 106 |
| abstract_inverted_index.through | 80 |
| abstract_inverted_index.weight. | 68 |
| abstract_inverted_index.Although | 1 |
| abstract_inverted_index.analysis | 79 |
| abstract_inverted_index.antibody | 88 |
| abstract_inverted_index.approved | 100 |
| abstract_inverted_index.atypical | 44 |
| abstract_inverted_index.combined | 16, 188 |
| abstract_inverted_index.decrease | 86 |
| abstract_inverted_index.disease. | 46 |
| abstract_inverted_index.efficacy | 112 |
| abstract_inverted_index.lesions, | 64 |
| abstract_inverted_index.observed | 55 |
| abstract_inverted_index.relapse. | 77 |
| abstract_inverted_index.steroids | 187 |
| abstract_inverted_index.vulgaris | 6 |
| abstract_inverted_index.Following | 47 |
| abstract_inverted_index.adenosine | 136 |
| abstract_inverted_index.adhesion. | 148 |
| abstract_inverted_index.anti-Dsg3 | 81 |
| abstract_inverted_index.diagnosed | 34 |
| abstract_inverted_index.effective | 20 |
| abstract_inverted_index.indicated | 83 |
| abstract_inverted_index.inhibitor | 99 |
| abstract_inverted_index.initially | 41 |
| abstract_inverted_index.mechanism | 165 |
| abstract_inverted_index.pemphigus | 5 |
| abstract_inverted_index.promising | 154 |
| abstract_inverted_index.psoriasis | 102 |
| abstract_inverted_index.rituximab | 15 |
| abstract_inverted_index.steroids, | 181 |
| abstract_inverted_index.therapies | 21 |
| abstract_inverted_index.treatment | 3, 159, 184 |
| abstract_inverted_index.Apremilast | 150 |
| abstract_inverted_index.Conclusion | 149 |
| abstract_inverted_index.Discussion | 94 |
| abstract_inverted_index.apremilast | 72, 92, 127 |
| abstract_inverted_index.colchicine | 50 |
| abstract_inverted_index.contribute | 142 |
| abstract_inverted_index.innovative | 164 |
| abstract_inverted_index.pemphigus, | 161 |
| abstract_inverted_index.rituximab. | 190 |
| abstract_inverted_index.stabilized | 67 |
| abstract_inverted_index.tolerance. | 173 |
| abstract_inverted_index.treatment, | 51, 109 |
| abstract_inverted_index.treatment. | 93, 130 |
| abstract_inverted_index.upregulate | 134 |
| abstract_inverted_index.67-year-old | 31 |
| abstract_inverted_index.Apremilast, | 95 |
| abstract_inverted_index.Behçet’s | 45, 104 |
| abstract_inverted_index.Observation | 29 |
| abstract_inverted_index.alternative | 179 |
| abstract_inverted_index.apremilast: | 60 |
| abstract_inverted_index.disease’s | 105 |
| abstract_inverted_index.improvement | 53 |
| abstract_inverted_index.significant | 52 |
| abstract_inverted_index.therapeutic | 155 |
| abstract_inverted_index.Introduction | 0 |
| abstract_inverted_index.demonstrated | 110 |
| abstract_inverted_index.highlighting | 123 |
| abstract_inverted_index.introduction | 58 |
| abstract_inverted_index.keratinocyte | 147 |
| abstract_inverted_index.misdiagnosed | 42 |
| abstract_inverted_index.unsuccessful | 49 |
| abstract_inverted_index.Retrospective | 78 |
| abstract_inverted_index.effectiveness | 125 |
| abstract_inverted_index.monophosphate | 137 |
| abstract_inverted_index.stabilization | 145 |
| abstract_inverted_index.Apremilast’s | 131 |
| abstract_inverted_index.revolutionized | 10 |
| abstract_inverted_index.discontinuation | 70 |
| abstract_inverted_index.corticosteroids, | 18 |
| abstract_inverted_index.phosphodiesterase | 97 |
| abstract_inverted_index.immunosuppression, | 170 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5046679600 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 10 |
| corresponding_institution_ids | https://openalex.org/I4210091279, https://openalex.org/I4210097159 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8500000238418579 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.94935882 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |